Trial Profile
A phase 2 study of mid-term compliance and effectiveness of dasatinib therapy in patients with chronic myeloid leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DARIA 01
- 06 Mar 2012 New trial record